Abstract
Изучалось прогностическое значение галектина-3 в развитии сердечно-сосудистых осложнений при 30-месячном наблюдении 155 больных с инфарктом миокарда правого желудочка на фоне Q-инфаркта задней стенки левого желудочка. Уровень галектина-3 определялся на 2-е сутки острого инфаркта и через 6 месяцев наблюдения (Platinun ELISA). Доказано прогностическое значение галектина-3 в развитии нестабильной стенокардии, повторных инфарктов миокарда, острых нарушений мозгового кровообращения и сердечно-сосудистой смерти в течение 30 месяцев. Установлена связь между высокой концентрацией галектина-3 через 6 месяцев после инфаркта правого желудочка и частотой комбинированной конечной точки.
Highlights
The use of biomarkers is widely accepted as tools for diagnosis and risk stratification
The combined endpoints included: unstable angina (UA), Re-MI, stroke and cardio-vascular death (CVD). 62 (40%) patients in whom the study endpoints occurred were included in grope 1st, 93 (60%) patients without ACVE composed grope 2nd
The significantly frequent comorbidities in 1st group patients were diabetes mellitus (DM) (38.7%, p = 0.0156), arterial hypertension (AH) (91.9%, p = 0.026) and peripheral atherosclerosis (25.8%, p = 0.0037)
Summary
The use of biomarkers is widely accepted as tools for diagnosis and risk stratification. A number of clinical studies have shown the use of galectin-3 as a risk marker of complications in patients with heart failure and ACVE in patients with acute coronary syndrome. The prognostic role of galectin-3 of patients with RV MI is still unknown.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
